CJC-1295 Research Guide: GHRH Analog, DAC Technology, and Growth Hormone Axis Biology

By Sam Smith

Native GHRH has a half-life of about 30 minutes. CJC-1295 with DAC has a half-life of 5.8 to 8.1 days. That difference — achieved through a maleimide-based Drug Affinity Complex that conjugates the peptide to circulating albumin in vivo — is one of the more elegant pharmacokinetic engineering solutions in the peptide research space. The 2006 paper by Sam Teichman and colleagues in the Journal of Clinical Endocrinology & Metabolism showed that a single injection of CJC-1295 elevated GH and IGF-1 levels for over two weeks in healthy adults, a duration no prior GHRH analog had come close to achieving. That's not a subtle improvement — it fundamentally changes how you design a GH-axis research protocol.

The naming situation around CJC-1295 is genuinely confusing and worth sorting out before going further. There are two distinct peptides frequently sold under related names: CJC-1295 with DAC (the long-acting albumin-binding compound described above) and CJC-1295 without DAC — also called Mod GRF 1-29 — which has similar amino acid substitutions but lacks the maleimide modification and has a much shorter half-life (around 30 minutes post-injection). These are pharmacologically different compounds with different dosing requirements. Conflating them produces meaningless data. Researchers comparing studies in the literature need to check which version was used; suppliers don't always make the distinction clear on product labels.

This guide covers how CJC-1295 works at the GHRH receptor, what DAC technology does to the pharmacokinetic profile, what the published research shows on GH and IGF-1 elevation, how the DAC and non-DAC versions differ practically, comparisons with sermorelin and ipamorelin, and what to look for when sourcing either compound. All claims link to primary sources.

What does CJC-1295 do to your body?

CJC-1295 binds the GHRH receptor on pituitary somatotrophs and triggers endogenous growth hormone release. The released GH then circulates and drives hepatic IGF-1 production. Published research shows that CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility, which is the key advantage over exogenous human growth hormone replacement: the natural pituitary pulse rhythm is maintained rather than overridden.

The downstream effects of elevated GH and IGF-1 include increased protein synthesis in skeletal muscle, lipolysis in visceral and subcutaneous adipose tissue, supportive effects on bone biology, and modulation of metabolic substrate selection. Published research shows that Serum GH and IGF-1 levels have been shown to increase with administration of GHRH analogs across multiple research and clinical contexts.

DAC technology and the extended half-life

The Drug Affinity Complex (DAC) modification is the key innovation in CJC-1295. According to the original PubMed-indexed pharmacology paper, identification of CJC-1295 as a stable and active hGRF(1-29) analog with an extended plasma half-life was achieved through conjugation of the GHRH(1-29) backbone with a reactive maleimide group that covalently binds free cysteines on circulating albumin. The bound peptide circulates with the long half-life of albumin itself.

Published research shows that the estimated half-life of CJC-1295 was 5.8-8.1 d in healthy human volunteers, compared with native GHRH’s 30-minute half-life. This is the longest half-life of any GHRH analogue in research and clinical use, and it allows the once-weekly dosing schedule that distinguishes CJC-1295 from sermorelin or tesamorelin.

CJC-1295 with DAC vs without DAC

The DAC and non-DAC versions differ structurally:

• CJC-1295 with DAC: maleimide-conjugated, binds albumin, ~6-day half-life, once-weekly dosing
• CJC-1295 without DAC (Mod GRF 1-29): same amino acid substitutions but no maleimide, ~30-minute half-life, multiple-times-daily dosing required for sustained effect

The practical difference matters for research design. CJC-1295 with DAC produces sustained, near-flat GH elevation over the dosing interval, partially overriding the natural pituitary pulse. CJC-1295 without DAC produces brief pulse-aligned GH releases, more closely mimicking native GHRH action. Published research shows that treatment with once-daily administration of CJC-1295 is able to maintain normal body composition and growth in research models, though most research now uses once-weekly DAC dosing.

How CJC-1295 and ipamorelin work together

The CJC-1295 and ipamorelin stack is the canonical research combination for body composition work. The two peptides engage different receptors and produce complementary effects:

• CJC-1295 binds the GHRH receptor and raises baseline GH and IGF-1
• Ipamorelin binds the ghrelin receptor (GHS-R1a) and triggers pulse GH release
• Combined, they provide both baseline-elevating and pulse-amplifying effects, more closely approximating physiological GH secretion
• Neither peptide’s mechanism is contained in the other; the combination produces additive rather than redundant effects

The pharmacokinetic mismatch (5-day half-life of CJC-1295 with DAC vs 2-hour half-life of ipamorelin) means that ipamorelin needs multi-daily dosing while CJC-1295 needs once-weekly. Pre-blended dose pens often combine specific microgram amounts of each in a single injection.

Benefits of the CJC-1295 + ipamorelin stack

Documented benefits in research protocols include:

• Sustained elevation of growth hormone and IGF-1 over the dosing interval
• Modest lean mass gains over 8-16 weeks of consistent dosing
• Fat loss particularly in visceral adipose tissue
• Improved sleep quality through alignment with the natural night-time GH pulse
• Modest improvements in skin elasticity attributed to IGF-1-mediated collagen synthesis
• Bone mineral content support in long-term protocols

Effect magnitudes are modest compared with exogenous GH replacement but the natural pulsatile pattern preserved by CJC-1295 + ipamorelin makes the stack a research alternative to direct HGH administration.

How does CJC-1295 make you feel?

Subjective effects of CJC-1295 administration are subtle. Reported user experiences include improved sleep depth, mild morning fatigue or “GH flu” in the first 1-2 weeks of dosing, increased appetite (modest), and gradual changes in body composition over months. There is no acute “high” or stimulant-like effect; the mechanism is gradual hormonal rebalancing rather than monoamine release. Some users report mild water retention and joint discomfort in early weeks, consistent with low-dose GH effects.

Side effects and safety

Reported side effects in research and clinical use are dominated by transient effects of the GH/IGF-1 elevation:

• Injection-site reactions (most common, 5-15 percent of users)
• Transient water retention and peripheral edema in early dosing
• Mild joint stiffness or discomfort during the GH-adaptation period
• Carpal tunnel-like symptoms in rare cases at higher doses
• Transient glucose elevation (because GH antagonises insulin signalling) — typically not clinically meaningful in non-diabetic populations

The early CJC-1295 clinical program included one reported death attributed to cardiac issues, which led to discontinuation of the original ConjuChem development. Subsequent research and compounded use has not confirmed a clinical-grade cardiac signal, but the historical event is part of the regulatory caution around the compound.

Dosage and administration

Research protocols typically use:

• CJC-1295 with DAC: 1-2 mg subcutaneous injection once weekly
• CJC-1295 without DAC (Mod GRF 1-29): 100-200 μg subcutaneous, two to three times daily, often stacked with ipamorelin

The peptide is supplied as a lyophilised powder for reconstitution in bacteriostatic water. Bedtime dosing is typical to align with natural night-time GH pulses. The pre-blended CJC-1295 + ipamorelin pen often delivers 100 μg of each in a single injection.

How long to see results from CJC-1295 therapy?

GH and IGF-1 elevations are measurable within days. Body composition changes appear over 8-16 weeks of consistent dosing. Sleep quality improvements are often reported within the first 2-3 weeks. Visible body recomposition (subtle fat loss, slightly increased muscle definition) typically requires 12 weeks or more.

Is CJC-1295 legal and safe to use?

CJC-1295 is not approved by Health Canada, the FDA, or the EMA as a finished pharmaceutical. Original development by ConjuChem was discontinued. The peptide was added to the FDA 503A “do not compound” list in 2023, restricting US compounding pharmacy preparation. Research-grade CJC-1295 is legal in Canada and the United States as a research chemical under research-use-only labelling. It is on the World Anti-Doping Agency prohibited list.

Sourcing for research

Reproducible GHRH-axis research depends on the integrity of the input material:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace
• Mass spectrometry verification of the expected molecular weight (3,367 Da for CJC-1295 with DAC; 3,367 Da for non-DAC)
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies CJC-1295 with third-party COA and HPLC purity confirmation, in both the standalone and the CJC-1295 + ipamorelin blend formats. View the CJC-1295 product page or the CJC-1295 + Ipamorelin Blend.

CJC-1295 questions

What does CJC-1295 do to your body?

CJC-1295 binds the GHRH receptor on pituitary somatotrophs, stimulates endogenous growth hormone release, and drives downstream IGF-1 production. Downstream effects include modest lean mass gain, visceral fat loss, sleep quality improvement, and bone mineral content support over months of consistent dosing.

What are the potential side effects of CJC-1295 and Ipamorelin?

Injection-site reactions (most common), transient water retention, mild joint discomfort, occasional carpal tunnel-like symptoms at higher doses, and transient glucose elevation. The historical CJC-1295 program included one reported death; subsequent research has not confirmed a clinical-grade cardiac signal.

How does CJC-1295 make you feel?

Subjective effects are subtle: improved sleep depth, mild morning fatigue or “GH flu” in the first 1-2 weeks, modest appetite increase, and gradual body composition shifts over months. No acute stimulant-like effects.

What is the difference between CJC-1295 with DAC and without DAC?

With DAC: ~6-day half-life via albumin binding, once-weekly dosing, sustained near-flat GH elevation. Without DAC (Mod GRF 1-29): ~30-minute half-life, multi-daily dosing, brief pulse-aligned GH releases that more closely mimic native GHRH.

How do CJC-1295 and ipamorelin work together?

CJC-1295 raises baseline GH through GHRH-receptor activation; ipamorelin triggers GH pulses through ghrelin-receptor activation. The two peptides engage different receptors and produce additive rather than redundant effects, more closely approximating physiological GH secretion than either alone.

Key data point: Teichman et al. (2006, JCEM) published Phase 1 data showing a single 2 mg/kg CJC-1295 (with DAC) SC injection sustained IGF-1 elevation above baseline for 28 days — a duration 100× longer than native GHRH and 4× longer than unmodified CJC-1295 — due to Drug Affinity Complex albumin binding extending circulating half-life from minutes to approximately 8 days.

Summary

CJC-1295 is the GHRH analogue with the longest plasma half-life in research use, achieved through DAC-mediated albumin binding. The DAC version supports once-weekly subcutaneous dosing; the non-DAC version mimics native GHRH with multi-daily dosing. Both versions stimulate endogenous growth hormone release through the pituitary GHRH receptor, raising IGF-1 and producing modest body composition effects over months. The CJC-1295 + ipamorelin stack is the canonical research combination for body recomposition work, pairing baseline-elevating (CJC-1295) with pulse-triggering (ipamorelin) mechanisms. Not approved as a finished pharmaceutical, added to the FDA 503A “do not compound” list in 2023, and on the WADA prohibited list. Research-grade material is legal in Canada and the United States under research-use-only labelling.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption.